- Home
- SGU vs AURA Comparison
SGU vs AURA Comparison
Compare SGU & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- AURA
- Stock Information
- Founded
- SGU 1995
- AURA 2007
- Country
- SGU United States
- AURA United States
- Employees
- SGU N/A
- AURA N/A
- Industry
- SGU Other Specialty Stores
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- AURA Health Care
- Exchange
- SGU Nasdaq
- AURA Nasdaq
- Market Cap
- SGU 447.6M
- AURA 370.1M
- IPO Year
- SGU 1995
- AURA 2021
- Fundamental
- Price
- SGU $12.75
- AURA $5.36
- Analyst Decision
- SGU
- AURA Strong Buy
- Analyst Count
- SGU 0
- AURA 4
- Target Price
- SGU N/A
- AURA $22.75
- AVG Volume (30 Days)
- SGU 38.9K
- AURA 482.7K
- Earning Date
- SGU 04-30-2025
- AURA 05-08-2025
- Dividend Yield
- SGU 5.36%
- AURA N/A
- EPS Growth
- SGU 69.46
- AURA N/A
- EPS
- SGU 1.36
- AURA N/A
- Revenue
- SGU $1,726,066,000.00
- AURA N/A
- Revenue This Year
- SGU N/A
- AURA N/A
- Revenue Next Year
- SGU N/A
- AURA N/A
- P/E Ratio
- SGU $9.36
- AURA N/A
- Revenue Growth
- SGU N/A
- AURA N/A
- 52 Week Low
- SGU $9.64
- AURA $4.84
- 52 Week High
- SGU $13.75
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- SGU 43.49
- AURA 37.19
- Support Level
- SGU $12.44
- AURA $4.84
- Resistance Level
- SGU $13.19
- AURA $5.82
- Average True Range (ATR)
- SGU 0.44
- AURA 0.48
- MACD
- SGU -0.05
- AURA 0.03
- Stochastic Oscillator
- SGU 36.94
- AURA 32.20
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.